1. Two students debate the signaling of the GLP-1 receptor (GLP-1R). To act correctly on its primary second-messenger pathway, which precise coupling must the GLP-1R use?
A) Gq coupling that activates phospholipase C and raises inositol trisphosphate (IP3) and diacylglycerol as the dominant second messengers
B) Gi coupling that inhibits adenylyl cyclase and lowers cyclic adenosine monophosphate (cAMP) below baseline
C) Intrinsic tyrosine kinase activity that autophosphorylates the receptor and recruits insulin receptor substrate proteins
D) Gs coupling that activates adenylyl cyclase and raises cyclic adenosine monophosphate (cAMP), which then engages protein kinase A (PKA) and EPAC2
E) Direct ligand-gated cation channel opening that admits calcium without any G protein intermediary
ANSWER: D
Rationale:
The GLP-1R couples primarily to Gs, activating adenylyl cyclase and raising cyclic adenosine monophosphate (cAMP); cAMP then engages protein kinase A (PKA) and the exchange protein EPAC2 to amplify insulin secretion. Discriminating this from the other coupling types is the foundational point.
Option A: Option A is incorrect because the GLP-1R does not act primarily through Gq/phospholipase C with IP3 and diacylglycerol as dominant messengers; that describes a different receptor class.
Option B: Option B is incorrect because the GLP-1R raises cAMP via Gs, rather than lowering it via Gi.
Option C: Option C is incorrect because the GLP-1R is a G protein-coupled receptor, not a receptor tyrosine kinase; intrinsic tyrosine kinase activity describes the insulin receptor.
Option E: Option E is incorrect because the GLP-1R is not a ligand-gated ion channel; calcium entry is a downstream consequence of cAMP/PKA signaling, not a direct channel effect of ligand binding.
2. A precise statement is required to describe how GLP-1 receptor agonists affect glucagon. Which statement is correct?
A) They suppress glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, so the suppression eases as glucose falls toward normal, preserving the counterregulatory glucagon response to hypoglycemia
B) They suppress glucagon secretion completely and continuously regardless of the prevailing glucose level, abolishing the counterregulatory response
C) They increase glucagon secretion to balance the rise in insulin and prevent hypoglycemia
D) They have no effect on glucagon and act solely through beta cell insulin release
E) They convert alpha cells into beta cells, eliminating glucagon output permanently
ANSWER: A
Rationale:
GLP-1 RAs suppress glucagon secretion from pancreatic alpha cells in a glucose-dependent manner. Because the suppression is gated by glucose, it eases as glucose falls toward normal, which preserves the protective counterregulatory glucagon response during hypoglycemia.
Option B: Option B is incorrect because the suppression is glucose-dependent, not complete and continuous; it does not abolish counterregulation.
Option C: Option C is incorrect because GLP-1 RAs suppress, rather than increase, glucagon secretion.
Option D: Option D is incorrect because GLP-1 RAs do have a direct alpha cell effect; glucagon suppression is a distinct mechanism beyond beta cell insulin release.
Option E: Option E is incorrect because alpha-to-beta cell transdifferentiation is not the mechanism; glucagon suppression occurs through receptor signaling, not permanent cellular conversion.
3. The appetite-suppressing effect of GLP-1 receptor agonists is mediated by a specific hypothalamic circuit. Which description is correct?
A) Activation of orexigenic NPY (neuropeptide Y)/AgRP (agouti-related peptide) neurons, which increases food intake offset by other effects
B) Inhibition of anorexigenic POMC (pro-opiomelanocortin) neurons, reducing satiety signaling
C) Inhibition of orexigenic NPY (neuropeptide Y)/AgRP (agouti-related peptide) neurons and activation of anorexigenic POMC (pro-opiomelanocortin) neurons in the arcuate nucleus, reducing food intake
D) Stimulation of the hypothalamic thirst center, which reduces food intake indirectly through fluid loading
E) Direct blockade of gastric stretch receptors, which is the sole driver of reduced intake with no central component
ANSWER: C
Rationale:
GLP-1R activation in the hypothalamic arcuate nucleus inhibits orexigenic NPY (neuropeptide Y)/AgRP (agouti-related peptide) neurons and activates anorexigenic POMC (pro-opiomelanocortin) neurons, producing a durable reduction in food intake that is the primary driver of weight loss.
Option A: Option A is incorrect because GLP-1R activation inhibits, rather than activates, the orexigenic NPY/AgRP neurons.
Option B: Option B is incorrect because POMC neurons are activated, not inhibited; activating them enhances satiety.
Option D: Option D is incorrect because the effect is mediated by appetite circuitry, not by stimulating a thirst center and fluid loading.
Option E: Option E is incorrect because the effect has a substantial central component; it is not driven solely by peripheral gastric stretch receptor blockade.
4. GLP-1 receptor activation in the kidney contributes to renoprotection through a specific transport effect in the proximal tubule. Which mechanism is correct?
A) Inhibition of the sodium-glucose cotransporter-2 (SGLT-2), producing glucosuria and osmotic diuresis
B) Stimulation of the renin-angiotensin-aldosterone system, raising intraglomerular pressure
C) Blockade of aquaporin water channels in the collecting duct, producing a free-water diuresis
D) Activation of the epithelial sodium channel (ENaC) in the distal nephron, increasing sodium retention
E) Inhibition of the sodium-hydrogen exchanger 3 (NHE3) in the proximal tubule, producing natriuresis and reducing intraglomerular pressure
ANSWER: E
Rationale:
In the kidney, GLP-1R activation reduces proximal tubular sodium reabsorption by inhibiting the sodium-hydrogen exchanger 3 (NHE3), producing natriuresis and lowering intraglomerular pressure; anti-inflammatory effects in podocytes and mesangial cells further contribute to renoprotection.
Option A: Option A is incorrect because SGLT-2 inhibition with glucosuria is the mechanism of SGLT-2 inhibitors, not of GLP-1R activation.
Option B: Option B is incorrect because GLP-1R activation does not produce renoprotection by stimulating the renin-angiotensin-aldosterone system and raising intraglomerular pressure; the effect lowers intraglomerular pressure.
Option C: Option C is incorrect because GLP-1 RAs do not act by blocking collecting-duct aquaporins to cause a free-water diuresis.
Option D: Option D is incorrect because activating ENaC to retain sodium is the opposite of the natriuretic NHE3-inhibition effect described.
5. A precise classification question distinguishes the structural origin of the GLP-1 receptor agonists. Which agent is correctly matched to its structural class?
A) Liraglutide is an exendin-4-based peptide derived from the Gila monster
B) Exenatide is an exendin-4-based peptide derived from the Gila monster, sharing about 53 percent homology with human GLP-1 and resisting dipeptidyl peptidase-4 (DPP-4) cleavage via its Gly2 N-terminus
C) Semaglutide is an exendin-4-based peptide with no homology to human GLP-1
D) Dulaglutide is an exendin-4-based peptide that is renally excreted intact
E) Albiglutide is an exendin-4-based peptide that requires twice-daily dosing
ANSWER: B
Rationale:
Exenatide is the exendin-4-based agent, derived from the Gila monster salivary peptide exendin-4, sharing about 53 percent sequence homology with human GLP-1 and resisting dipeptidyl peptidase-4 (DPP-4) cleavage because of its glycine-2 (Gly2) N-terminal residue.
Option A: Option A is incorrect because liraglutide is a human GLP-1-based agent (with a Lys34Arg substitution and a fatty acid modification), not an exendin-4-based peptide.
Option C: Option C is incorrect because semaglutide is a human GLP-1-based agent and does share homology with human GLP-1; it is not exendin-4-based with no homology.
Option D: Option D is incorrect because dulaglutide is a human GLP-1-Fc fusion molecule cleared by reticuloendothelial catabolism, not an exendin-4 peptide excreted renally intact.
Option E: Option E is incorrect because albiglutide is a human GLP-1-albumin fusion dosed weekly, not an exendin-4-based twice-daily peptide.
6. Liraglutide is dosed once daily, unlike the once-weekly agents. Which structural and pharmacokinetic description of liraglutide is correct?
A) An IgG4 fragment crystallizable (Fc) fusion molecule with a half-life of about 7 days
B) An unmodified copy of native GLP-1 with a half-life of a few minutes
C) A microsphere suspension that releases drug over 7 days
D) A human GLP-1-based peptide with a Lys34Arg substitution and a fatty acid modification enabling reversible albumin binding, giving a half-life of approximately 13 hours and once-daily dosing
E) An oral peptide co-formulated with SNAC for gastric absorption
ANSWER: D
Rationale:
Liraglutide is a human GLP-1-based peptide carrying a Lys34Arg substitution and a fatty acid modification (attached via a glutamic acid linker) that enables reversible albumin binding, slowing clearance and proteolysis. This extends its half-life to roughly 13 hours, supporting once-daily subcutaneous dosing.
Option A: Option A is incorrect because the IgG4 Fc-fusion strategy with a roughly 7-day half-life describes dulaglutide, not liraglutide.
Option B: Option B is incorrect because liraglutide is structurally modified for albumin binding and does not have the minutes-long half-life of native GLP-1.
Option C: Option C is incorrect because a microsphere depot describes exenatide extended-release, not liraglutide.
Option E: Option E is incorrect because SNAC co-formulation for oral gastric absorption describes oral semaglutide, whereas liraglutide is injected once daily.
7. Distinguishing the duration of action across GLP-1 receptor agonists is essential for dosing. Which half-life pairing is correct?
A) Subcutaneous semaglutide has a half-life of approximately 165 to 184 hours (about 7 days), supporting weekly dosing, whereas twice-daily exenatide has a half-life of approximately 2 to 4 hours
B) Subcutaneous semaglutide has a half-life of approximately 2 to 4 hours, requiring twice-daily dosing
C) Twice-daily exenatide has a half-life of approximately 7 days
D) Liraglutide has a half-life of approximately 7 days, supporting weekly dosing
E) All GLP-1 receptor agonists share an identical half-life of approximately 24 hours regardless of structure
ANSWER: A
Rationale:
Subcutaneous semaglutide has a half-life of approximately 165 to 184 hours (about 7 days), which supports once-weekly dosing, while twice-daily exenatide has a short half-life of approximately 2 to 4 hours, accounting for its frequent dosing.
Option B: Option B is incorrect because the 2 to 4 hour half-life belongs to twice-daily exenatide, not semaglutide.
Option C: Option C is incorrect because twice-daily exenatide is short-acting, not a 7-day agent.
Option D: Option D is incorrect because liraglutide is once-daily with a half-life of about 13 hours, not a weekly 7-day agent.
Option E: Option E is incorrect because half-lives differ markedly across the class by structural strategy; they are not uniformly about 24 hours.
8. Each long-acting GLP-1 receptor agonist achieves its duration by a distinct strategy. Which agent-to-strategy match is correct?
A) Semaglutide achieves weekly dosing by fusion to an IgG4 fragment crystallizable (Fc) region
B) Exenatide extended-release achieves weekly dosing by reversible albumin binding through a fatty acid chain
C) Dulaglutide achieves weekly dosing by fusing two modified GLP-1 peptides to an immunoglobulin G4 (IgG4) fragment crystallizable (Fc) region, producing a large molecule that resists proteolysis and clears slowly by reticuloendothelial catabolism
D) Liraglutide achieves weekly dosing by encapsulation in extended-release microspheres
E) Oral semaglutide achieves weekly dosing because SNAC permanently prolongs its plasma half-life to 7 days
ANSWER: C
Rationale:
Dulaglutide achieves once-weekly dosing by fusing two modified GLP-1 peptides to an immunoglobulin G4 (IgG4) fragment crystallizable (Fc) region. The resulting large molecule (about 59 kDa) resists proteolysis and is cleared slowly through reticuloendothelial catabolism.
Option A: Option A is incorrect because semaglutide achieves its duration through fatty-acid-mediated reversible albumin binding, not Fc fusion.
Option B: Option B is incorrect because exenatide extended-release achieves weekly dosing through a microsphere suspension, not albumin binding.
Option D: Option D is incorrect because liraglutide is once-daily and uses reversible albumin binding, not microsphere encapsulation, and is not a weekly agent.
Option E: Option E is incorrect because SNAC enables gastric absorption of oral semaglutide rather than permanently prolonging its half-life, and oral semaglutide is dosed daily, not weekly.
9. Oral semaglutide overcomes the usual barrier to oral peptide delivery through a specific co-formulated excipient. Which description of that excipient and its action is correct?
A) An enteric coating that resists gastric acid and dissolves only in the distal small intestine
B) A bile acid conjugate that promotes micellar uptake of the peptide in the jejunum
C) A lipid nanoparticle carrier that fuses with enterocyte membranes in the ileum
D) A proteolytic enzyme inhibitor mixed into the tablet that neutralizes intestinal peptidases throughout the gut
E) SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate), an absorption enhancer that transiently permeabilizes the gastric mucosa and raises local pH, enabling transcellular gastric absorption before proteolytic degradation
ANSWER: E
Rationale:
Oral semaglutide is co-formulated with SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate), an absorption enhancer that transiently permeabilizes the gastric mucosa and raises local pH, allowing transcellular absorption of semaglutide across the gastric epithelium before proteolytic degradation occurs.
Option A: Option A is incorrect because absorption depends on SNAC-mediated gastric uptake, not an enteric coating releasing drug in the distal small intestine.
Option B: Option B is incorrect because the enhancer is SNAC, not a bile acid conjugate promoting jejunal micellar uptake.
Option C: Option C is incorrect because the mechanism is SNAC-mediated gastric permeabilization, not a lipid nanoparticle fusing with ileal enterocytes.
Option D: Option D is incorrect because the formulation relies on SNAC-mediated absorption, not a broad proteolytic enzyme inhibitor neutralizing peptidases throughout the gut.
10. Short-acting and long-acting GLP-1 receptor agonists differ in their dominant pharmacodynamic effect. Which contrast is stated correctly?
A) Short-acting agents lower fasting glucose chiefly through sustained glucagon suppression, while long-acting agents act only postprandially
B) Short-acting agents (such as twice-daily exenatide) produce prominent slowing of gastric emptying with predominant postprandial glucose lowering, whereas long-acting agents undergo gastric-emptying tachyphylaxis and shift toward fasting glucose lowering via sustained glucagon suppression
C) Both short-acting and long-acting agents maintain identical, continuous slowing of gastric emptying for the life of therapy
D) Long-acting agents produce the strongest acute gastric-emptying effect at every dose because of their higher potency
E) Short-acting agents have no effect on gastric emptying and act purely by increasing renal glucose excretion
ANSWER: B
Rationale:
Short-acting agents such as twice-daily exenatide most prominently slow gastric emptying during the prandial period, producing predominant postprandial glucose lowering (and the most injection-associated gastrointestinal effects). Long-acting agents produce continuous receptor stimulation, so the gastric-emptying effect undergoes tachyphylaxis and the glucose-lowering contribution shifts toward fasting glucose suppression via sustained glucagon inhibition.
Option A: Option A is incorrect because it reverses the two profiles; fasting suppression via glucagon characterizes long-acting agents, not short-acting ones.
Option C: Option C is incorrect because the gastric-emptying effect of long-acting agents wanes through tachyphylaxis rather than remaining identical and continuous.
Option D: Option D is incorrect because long-acting agents do not maintain the strongest acute gastric-emptying effect at every dose; that effect is most prominent with short-acting agents and declines with sustained exposure.
Option E: Option E is incorrect because short-acting agents do slow gastric emptying and do not act by increasing renal glucose excretion.
11. The nausea that commonly accompanies GLP-1 receptor agonist initiation has a definable mechanistic basis. Which statement correctly characterizes it?
A) It is mechanism-based, arising from GLP-1R-mediated slowing of gastric emptying and central area postrema activation, and it is dose-dependent and typically diminishes over weeks as gastric GLP-1R tachyphylaxis develops
B) It is an immunoglobulin E-mediated allergic reaction that worsens progressively with continued exposure
C) It is an idiosyncratic, dose-independent reaction unrelated to the drug's pharmacology
D) It results from direct corrosive injury to the gastric mucosa caused by the injected peptide
E) It is caused by drug-induced hypoglycemia and resolves only with glucose administration
ANSWER: A
Rationale:
The nausea is mechanism-based: it arises from the same GLP-1R actions that produce benefit, namely slowing of gastric emptying and activation of the central area postrema (a circumventricular emetic region). It is dose-dependent, most pronounced early, and typically diminishes over weeks as gastric GLP-1R tachyphylaxis develops, which is why gradual titration is used.
Option B: Option B is incorrect because the nausea is a predictable pharmacologic effect, not an immunoglobulin E-mediated allergic reaction that worsens over time.
Option C: Option C is incorrect because the effect is dose-dependent and directly related to the drug's pharmacology, not idiosyncratic.
Option D: Option D is incorrect because the nausea is not due to corrosive mucosal injury from the peptide.
Option E: Option E is incorrect because the nausea is not caused by hypoglycemia; GLP-1 RAs do not cause hypoglycemia as monotherapy, and the nausea reflects gastric and central mechanisms.
12. Precise discrimination of contraindication status is required for GLP-1 receptor agonists. Which statement is correct?
A) A prior episode of acute pancreatitis is an absolute contraindication that permanently bars all GLP-1 receptor agonists
B) Established atherosclerotic cardiovascular disease is an absolute contraindication to the class
C) A body mass index above 30 is an absolute contraindication to the class
D) A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome is an absolute (black-box) contraindication, whereas a history of pancreatitis is a caution rather than an absolute contraindication in patients without ongoing pancreatic disease
E) Chronic kidney disease at any stage is an absolute contraindication to the entire class
ANSWER: D
Rationale:
A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome is an absolute, black-box contraindication to all GLP-1 RAs. By contrast, a history of pancreatitis is a precaution: the agents are used with caution and discontinued if acute pancreatitis is confirmed, but prior pancreatitis is not classified as an absolute contraindication in patients without ongoing pancreatic disease.
Option A: Option A is incorrect because prior pancreatitis is a caution, not a permanent absolute bar to the class.
Option B: Option B is incorrect because established atherosclerotic cardiovascular disease is an indication for preferred use, not a contraindication.
Option C: Option C is incorrect because an elevated body mass index is not a contraindication; obesity is often a reason to favor these agents.
Option E: Option E is incorrect because chronic kidney disease is not a blanket contraindication; most agents are used across CKD stages, with exenatide the low-eGFR exception.
13. Beyond gastrointestinal upset, GLP-1 receptor agonists carry a specific hepatobiliary safety signal. Which association is correct?
A) An increased risk of hemolytic anemia due to direct red cell membrane injury
B) An increased risk of pulmonary fibrosis from chronic receptor activation in the lung
C) An increased risk of cholelithiasis and cholecystitis, attributed to reduced gallbladder motility and increased biliary lithogenicity, particularly at higher doses and with greater weight loss
D) An increased risk of nephrolithiasis from drug-induced hypercalciuria
E) An increased risk of cataract formation from osmotic lens changes
ANSWER: C
Rationale:
GLP-1 RAs reduce gallbladder motility through central and direct GLP-1R effects, increasing biliary lithogenicity. Meta-analyses show an approximately 25 to 40 percent increased risk of cholelithiasis and cholecystitis, particularly at higher doses and with greater weight loss, so patients should be counseled about biliary symptoms.
Option A: Option A is incorrect because hemolytic anemia from red cell membrane injury is not a recognized effect of the class.
Option B: Option B is incorrect because pulmonary fibrosis is not an established GLP-1 RA adverse effect.
Option D: Option D is incorrect because the biliary signal is cholelithiasis, not nephrolithiasis from hypercalciuria.
Option E: Option E is incorrect because cataract formation from osmotic lens changes is not a characteristic class effect; the recognized hepatobiliary signal is gallbladder disease.
14. A precise statement about hypoglycemia risk with GLP-1 receptor agonists is needed. Which statement is correct?
A) GLP-1 receptor agonists cause hypoglycemia even as monotherapy because they stimulate insulin release continuously
B) GLP-1 receptor agonists do not cause hypoglycemia as monotherapy because their insulinotropic effect is glucose-dependent, but hypoglycemia risk rises when they are combined with a sulfonylurea or insulin, whose insulin effect is not glucose-gated
C) GLP-1 receptor agonists cause hypoglycemia only when combined with metformin, which independently lowers glucose
D) GLP-1 receptor agonists prevent hypoglycemia under all circumstances, including when combined with insulin
E) GLP-1 receptor agonists cause hypoglycemia only when combined with an SGLT-2 inhibitor
ANSWER: B
Rationale:
GLP-1 RAs do not cause hypoglycemia as monotherapy because their insulin-secretory effect is strictly glucose-dependent. However, when combined with a sulfonylurea or insulin (whose insulin effect is fixed or semi-fixed and not glucose-gated), the added secretagogue or exogenous insulin can produce hypoglycemia, especially if appetite suppression reduces food intake; preemptive dose reduction of the sulfonylurea or insulin is standard.
Option A: Option A is incorrect because monotherapy does not cause hypoglycemia; the insulinotropic effect is glucose-dependent, not continuous.
Option C: Option C is incorrect because metformin does not cause hypoglycemia and combining it with a GLP-1 RA does not create hypoglycemia risk.
Option D: Option D is incorrect because GLP-1 RAs do not prevent hypoglycemia under all circumstances; combined with insulin they can contribute to it.
Option E: Option E is incorrect because SGLT-2 inhibitors do not cause hypoglycemia, so that combination is not the basis of risk; sulfonylureas and insulin are.
15. The cardiovascular benefit of GLP-1 receptor agonists is mechanistically distinct from that of SGLT-2 inhibitors. Which contrast is correct?
A) GLP-1 receptor agonists act primarily by reducing heart failure hospitalization through cardiac unloading, just as SGLT-2 inhibitors do
B) Both classes act mainly by lowering HbA1c, and their cardiovascular benefits are interchangeable
C) GLP-1 receptor agonists provide benefit only through weight loss, with no vascular component
D) SGLT-2 inhibitors act primarily through an anti-atherosclerotic, stroke-predominant mechanism, while GLP-1 receptor agonists act through diuresis
E) GLP-1 receptor agonists produce a predominantly anti-atherosclerotic, anti-inflammatory benefit with a stroke-predominant reduction in major adverse cardiovascular events and no clear heart failure hospitalization reduction, whereas SGLT-2 inhibitors reduce heart failure hospitalization through cardiac unloading
ANSWER: E
Rationale:
GLP-1 RA cardiovascular benefit is believed to be predominantly anti-atherosclerotic and anti-inflammatory, with a stroke-predominant reduction in major adverse cardiovascular events and no clear reduction in heart failure hospitalization. SGLT-2 inhibitors, by contrast, reduce heart failure hospitalization through cardiac unloading and glycosuric/natriuretic effects, a mechanistically distinct profile.
Option A: Option A is incorrect because GLP-1 RAs do not act primarily by reducing heart failure hospitalization through cardiac unloading; that is the SGLT-2 inhibitor profile.
Option B: Option B is incorrect because the cardiovascular benefit of GLP-1 RAs is not explained mainly by HbA1c lowering and is not interchangeable with the SGLT-2 inhibitor mechanism.
Option C: Option C is incorrect because the benefit is not attributable to weight loss alone; direct vascular and anti-inflammatory effects contribute.
Option D: Option D is incorrect because it reverses the two mechanisms; the anti-atherosclerotic, stroke-predominant pattern belongs to GLP-1 RAs, and SGLT-2 inhibitors do not act mainly through that pathway.
16. A precise statement about GLP-1 receptor agonists and renal function is required. Which statement is correct?
A) Most GLP-1 receptor agonists require no dose adjustment across most stages of renal impairment, but exenatide is the exception and is generally avoided when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73m2 because of its greater renal clearance
B) All GLP-1 receptor agonists must be dose-reduced once the eGFR falls below 60 mL/min/1.73m2
C) Dulaglutide is the agent that must be avoided below an eGFR of 30 because it is filtered and excreted intact by the kidney
D) Semaglutide is contraindicated at any degree of renal impairment because it is fully renally cleared
E) GLP-1 receptor agonists are eliminated identically by the kidney, so the same renal threshold applies uniformly to every agent
ANSWER: A
Rationale:
Most GLP-1 RAs are generally safe without dose adjustment across most stages of renal impairment, an advantage over metformin and sulfonylureas. Exenatide is the exception, being cleared renally to a greater degree, so it is generally avoided when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73m2.
Option B: Option B is incorrect because the class does not uniformly require dose reduction below an eGFR of 60; most agents need no adjustment through CKD stages 1 to 4.
Option C: Option C is incorrect because the low-eGFR exception is exenatide, not dulaglutide; dulaglutide is a large Fc-fusion molecule cleared by reticuloendothelial catabolism.
Option D: Option D is incorrect because semaglutide is not contraindicated at any renal impairment and is in fact studied and used in chronic kidney disease.
Option E: Option E is incorrect because the agents are not eliminated identically; renal handling differs by structural class, so a single uniform threshold does not apply.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.